The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.
Original Article: FDA Grants Brigatinib Priority Review for Frontline ALK+ NSCLC